Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of once-weekly MK-3102 monotherapy versus placebo in adults with type 2 diabetes mellitus
NL-OMON40348Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in type 2 diabetes mellitus (T2DM) comparing MK-3102 once weekly with Placebo once weekly (2 arms). Primary endpoints: Change in HbA1c at Week 24 and Safety and tolerability. Started Jun 2013; status: active, not recruiting.
02
Drugs
omarigliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON40348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40348.